Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 5/2017

01.05.2017 | Movement Disorders (S Fox, Section Editor)

Multiple System Atrophy - State of the Art

verfasst von: Brice Laurens, Sylvain Vergnet, Miguel Cuina Lopez, Alexandra Foubert-Samier, François Tison, Pierre-Olivier Fernagut, Wassilios G. Meissner

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder that is characterized by a variable combination of parkinsonism, cerebellar impairment, and autonomic dysfunction. Some symptomatic treatments are available while neuroprotection or disease-modification remain unmet treatment needs. The pathologic hallmark is the accumulation of aggregated alpha-synuclein (α-syn) in oligodendrocytes forming glial cytoplasmic inclusions, which qualifies MSA as synucleinopathy together with Parkinson’s disease and dementia with Lewy bodies. Despite progress in our understanding of the pathogenesis of MSA, the origin of α-syn aggregates in oligodendrocytes is still a matter of an ongoing debate. We critically review here studies published in the field over the past 5 years dealing with pathogenesis, genetics, clinical signs, biomarker for improving diagnostic accuracy, and treatment development.
Literatur
1.
Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670–6.CrossRefPubMedPubMedCentral
2.
Fernagut PO, Dehay B, Maillard A, Bezard E, Perez P, Pavy-Le Traon A, et al. Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiol Dis. 2014;67:133–9.CrossRefPubMed
3.
Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci. 1989;94(1/3):79–100.CrossRefPubMed
4.
Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain. 1994;117(Pt 2):235–43.CrossRefPubMed
5.
Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett. 1998;251(3):205–8.CrossRefPubMed
6.
Salvesen L, Ullerup BH, Sunay FB, Brudek T, Lokkegaard A, Agander TK, et al. Changes in total cell numbers of the basal ganglia in patients with multiple system atrophy—a stereological study. Neurobiol Dis. 2015;74:104–13.CrossRefPubMed
7.
Cykowski MD, Coon EA, Powell SZ, Jenkins SM, Benarroch EE, Low PA, et al. Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain. 2015;138(Pt 8):2293–309.CrossRefPubMedPubMedCentral
8.
• Asi YT, Simpson JE, Heath PR, Wharton SB, Lees AJ, Revesz T, et al. Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia. 2014;62(6):964–70. SNCA gene expression was assessed in several brain regions in patients with MSA, PD and healthy controls. Highest expression was found in the cortex and lowest in the putamen, with no differences observed between groups. SNCA expression was similarly found in neurons and oligodendrocytes.CrossRefPubMedPubMedCentral
9.
• May VE, Ettle B, Poehler AM, Nuber S, Ubhi K, Rockenstein E, et al. alpha-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy. Neurobiol Aging. 2014;35(10):2357–68. Post-mortem study describing α-syn deposits in OPCs and an increased number of striatal OPCs in MSA patients.CrossRefPubMedPubMedCentral
10.
• Djelloul M, Holmqvist S, Boza-Serrano A, Azevedo C, Yeung MS, Goldwurm S, et al. Alpha-synuclein expression in the oligodendrocyte lineage: an in vitro and in vivo study using rodent and human models. Stem Cell Reports. 2015;5(2):174–84. Comprehensive in-vitro characterization showing α-syn protein and its transcripts in oligodendrocytes generated from mouse and human embryonic stem cells, in induced pluripotent stem cells derived from fibroblasts of MSA patients and in oligodendrocytes of adult MSA brains.CrossRefPubMedPubMedCentral
11.
Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia. 2014;62(3):387–98.CrossRefPubMed
12.
Kisos H, Pukass K, Ben-Hur T, Richter-Landsberg C, Sharon R. Increased neuronal alpha-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling alpha-synucleinopathies. PLoS One. 2012;7(10), e46817.CrossRefPubMedPubMedCentral
13.
Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, et al. Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015;14(8):855–66.CrossRefPubMedPubMedCentral
14.
Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci USA. 2013;110(48):19555–60.CrossRefPubMedPubMedCentral
15.
Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A. 2015;112(38):E5308–17.CrossRefPubMedPubMedCentral
16.
Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522(7556):340–4.CrossRefPubMed
17.
Ahmed Z, Asi YT, Lees AJ, Revesz T, Holton JL. Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and Parkinson's disease. Brain Pathol. 2013;23(3):263–73.CrossRefPubMed
18.
Song YJ, Lundvig DM, Huang Y, Gai WP, Blumbergs PC, Hojrup P, et al. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol. 2007;171(4):1291–303.CrossRefPubMedPubMedCentral
19.
Ota K, Obayashi M, Ozaki K, Ichinose S, Kakita A, Tada M, et al. Relocation of p25alpha/tubulin polymerization promoting protein from the nucleus to the perinuclear cytoplasm in the oligodendroglia of sporadic and COQ2 mutant multiple system atrophy. Acta Neuropathol Commun. 2014;2:136.PubMedPubMedCentral
20.
Vieira BD, Radford RA, Chung RS, Guillemin GJ, Pountney DL. Neuroinflammation in multiple system atrophy: response to and cause of alpha-synuclein aggregation. Front Cell Neurosci. 2015;9:437.CrossRefPubMedPubMedCentral
21.
Radford R, Rcom-H'cheo-Gauthier A, Wong MB, Eaton ED, Quilty M, Blizzard C, et al. The degree of astrocyte activation in multiple system atrophy is inversely proportional to the distance to alpha-synuclein inclusions. Mol Cell Neurosci. 2015;65:68–81.CrossRefPubMed
22.
23.
Pukass K, Goldbaum O, Richter-Landsberg C. Mitochondrial impairment and oxidative stress compromise autophagosomal degradation of alpha-synuclein in oligodendroglial cells. J Neurochem. 2015;135(1):194–205.CrossRefPubMed
24.
Bassil F, Canron MH, Vital A, Bezard E, Yazhou L, Greig NH, et al. Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain. 2017; doi:10.​1093/​brain/​awx044.
25.
• Multiple-system atrophy research collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med. 2013;369(3):233–44. Description of a homozygous mutation and compound heterozygous mutations in the COQ2 gene in two multiplex families with MSA. Additional studies including cohorts from Asia have not confirmed or only partly replicated these findings.CrossRef
26.
Schottlaender LV, Houlden H, Multiple-System Atrophy Brain Bank C. Mutant COQ2 in multiple-system atrophy. N Engl J Med. 2014;371(1):81.PubMed
27.
Jeon BS, Farrer MJ, Bortnick SF, Korean Canadian Alliance on Parkinson's disease, related disease. Mutant COQ2 in multiple-system atrophy. N Engl J Med. 2014;371(1):80.CrossRefPubMed
28.
Sharma M, Wenning G, Kruger R. European multiple-system atrophy study, G. Mutant COQ2 in multiple-system atrophy. N Engl J Med. 2014;371(1):80–1.CrossRefPubMed
29.
Ogaki K, Fujioka S, Heckman MG, Rayaprolu S, Soto-Ortolaza AI, Labbe C, et al. Analysis of COQ2 gene in multiple system atrophy. Mol Neurodegener. 2014;9:44.CrossRefPubMedPubMedCentral
30.
Lin CH, Tan EK, Yang CC, Yi Z, Wu RM. COQ2 gene variants associate with cerebellar subtype of multiple system atrophy in Chinese. Mov Disord. 2015;30(3):436–7.CrossRefPubMed
31.
Sun Z, Ohta Y, Yamashita T, Sato K, Takemoto M, Hishikawa N, et al. New susceptible variant of COQ2 gene in Japanese patients with sporadic multiple system atrophy. Neurol Genet. 2016;2(2), e54.CrossRefPubMedPubMedCentral
32.
Ronchi D, Di Biase E, Franco G, Melzi V, Del Sorbo F, Elia A, et al. Mutational analysis of COQ2 in patients with MSA in Italy. Neurobiol Aging. 2016;45:213. e1-2.
33.
Barca E, Kleiner G, Tang G, Ziosi M, Tadesse S, Masliah E, et al. Decreased coenzyme Q10 levels in multiple system atrophy cerebellum. J Neuropathol Exp Neurol. 2016;75(7):663–72.CrossRefPubMed
34.
Schottlaender LV, Bettencourt C, Kiely AP, Chalasani A, Neergheen V, Holton JL, et al. Coenzyme Q10 levels are decreased in the cerebellum of multiple-system atrophy patients. PLoS One. 2016;11(2), e0149557.CrossRefPubMedPubMedCentral
35.
Mitsui J, Matsukawa T, Sasaki H, Yabe I, Matsushima M, Durr A, et al. Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol. 2015;2(4):417–26.CrossRefPubMedPubMedCentral
36.
Sun Z, Jiang H, Jiao B, Hou X, Shen L, Xia K, et al. C9orf72 hexanucleotide expansion analysis in Chinese patients with multiple system atrophy. Parkinsonism Relat Disord. 2015;21(7):811–2.CrossRefPubMed
37.
Chelban V, Manole A, Pihlstrom L, Schottlaender L, Efthymiou S, Connor EO, et al. Analysis of the prion protein gene in multiple system atrophy. Neurobiol Aging. 2017;49:216 e15–e18.CrossRef
38.
Scholz SW, Majounie E, Revesz T, Holton JL, Okun MS, Houlden H, et al. Multiple system atrophy is not caused by C9orf72 hexanucleotide repeat expansions. Neurobiol Aging. 2015;36(2):1223 e1–2.CrossRef
39.
Chen X, Chen Y, Wei Q, Ou R, Cao B, Zhao B, et al. C9ORF72 repeat expansions in Chinese patients with Parkinson's disease and multiple system atrophy. J Neural Transm (Vienna). 2016.
40.
• Sailer A, Scholz SW, Nalls MA, Schulte C, Federoff M, Price TR, et al. A genome-wide association study in multiple system atrophy. Neurology. 2016;87(15):1591–8. Largest GWAS including 918 MSA patients. No association was found for any of the assessed genes, which may partly be explained by the still relatively low number of assessed cases. Several loci were identified for future follow-up in larger sample series including the genes FBXO47, ELOVL7, EDN1 and MAPT.
41.
Pavy-Le Traon A, Piedvache A, Perez-Lloret S, Calandra-Buonaura G, Cochen-De Cock V, Colosimo C, et al. New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. J Neurol Neurosurg Psychiatry. 2016;87(5):554–61.CrossRefPubMed
42.
• Giannini G, Calandra-Buonaura G, Mastrolilli F, Righini M, Bacchi-Reggiani ML, Cecere A, et al. Early stridor onset and stridor treatment predict survival in 136 patients with MSA. Neurology. 2016;87(13):1375–83. Large retrospective series of 136 MSA patients among whom 42 presented with stridor. Patients with stridor onset within the first three years showed shorter survival. Thirty-one patients were treated with tracheotomy or continous positive airway pressure (CPAP). Treatment had a positive effect on survival with tracheotomy being more effective than CPAP.CrossRefPubMed
43.
Flabeau O, Ghorayeb I, Perez P, Maillard A, Taillard J, Philip P, et al. Impact of sleep apnea syndrome on survival in patients with multiple system atrophy. Parkinsonism Relat Disord. 2017;35:92–95.
44.
Wang Y, Shao WB, Gao L, Lu J, Gu H, Sun LH, et al. Abnormal pulmonary function and respiratory muscle strength findings in Chinese patients with Parkinson's disease and multiple system atrophy—comparison with normal elderly. PLoS One. 2014;9(12), e116123.CrossRefPubMedPubMedCentral
45.
Teive HA, Arruda WO, Moro A, Moscovich M, Munhoz RP. Differential diagnosis of sporadic adult-onset ataxia: the role of REM sleep behavior disorder. Parkinsonism Relat Disord. 2015;21(6):640–3.CrossRefPubMed
46.
Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK. Premotor signs and symptoms of multiple system atrophy. Lancet Neurol. 2012;11(4):361–8.CrossRefPubMed
47.
Kass-Iliyya L, Kobylecki C, McDonald KR, Gerhard A, Silverdale MA. Pain in multiple system atrophy and progressive supranuclear palsy compared to Parkinson's disease. Brain Behav. 2015;5(5), e00320.CrossRefPubMedPubMedCentral
48.
Stankovic I, Krismer F, Jesic A, Antonini A, Benke T, Brown RG, et al. Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord. 2014;29(7):857–67.CrossRefPubMedPubMedCentral
49.
• Auzou N, Dujardin K, Biundo R, Foubert-Samier A, Barth C, Duval F, et al. Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia. Parkinsonism Relat Disord. 2015;21(10):1273–7. This study applied PDD procedures in 111 MSA patients and found that the short screening test may be useful for the diagnosis of MSA dementia, keeping in mind that cognitive impairment is a non-supporting feature of current diagnosis criteria for MSA.CrossRefPubMed
50.
Koga S, Aoki N, Uitti RJ, van Gerpen JA, Cheshire WP, Josephs KA, et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology. 2015;85(5):404–12.CrossRefPubMedPubMedCentral
51.
Asi YT, Ling H, Ahmed Z, Lees AJ, Revesz T, Holton JL. Neuropathological features of multiple system atrophy with cognitive impairment. Mov Disord. 2014;29(7):884–8.CrossRefPubMed
52.
Lee YC, Liu CS, Wu HM, Wang PS, Chang MH, Soong BW. The “hot cross bun” sign in the patients with spinocerebellar ataxia. Eur J Neurol. 2009;16(4):513–6.CrossRefPubMed
53.
Kraft E, Trenkwalder C, Auer DP. T2*-weighted MRI differentiates multiple system atrophy from Parkinson's disease. Neurology. 2002;59(8):1265–7.CrossRefPubMed
54.
Deguchi K, Ikeda K, Kume K, Takata T, Kokudo Y, Kamada M, et al. Significance of the hot-cross bun sign on T2*-weighted MRI for the diagnosis of multiple system atrophy. J Neurol. 2015;262(6):1433–9.CrossRefPubMed
55.
• Scherfler C, Gobel G, Muller C, Nocker M, Wenning GK, Schocke M, et al. Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. Neurology. 2016;86(13):1242–9. MRI study performing automated volume measures of 22 subcortical regions in patients with MSA, PD and PSP. Midbrain, putamen, and cerebellum were the most useful regions to construct a prediction model. This model was tested in a validation set in which all MSA patients were correctly classified.CrossRefPubMed
56.
Barbagallo G, Sierra-Pena M, Nemmi F, Traon AP, Meissner WG, Rascol O, et al. Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Mov Disord. 2016;31(3):325–34.CrossRefPubMed
57.
Nagayama H, Ueda M, Yamazaki M, Nishiyama Y, Hamamoto M, Katayama Y. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord. 2010;25(11):1744–7.CrossRefPubMed
58.
Laurens B, Constantinescu R, Freeman R, Gerhard A, Jellinger K, Jeromin A, et al. Fluid biomarkers in multiple system atrophy: a review of the MSA Biomarker Initiative. Neurobiol Dis. 2015;80:29–41.CrossRefPubMed
59.
Doppler K, Ebert S, Uceyler N, Trenkwalder C, Ebentheuer J, Volkmann J, et al. Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology. Acta Neuropathol. 2014;128(1):99–109.CrossRefPubMedPubMedCentral
60.
Donadio V, Incensi A, Leta V, Giannoccaro MP, Scaglione C, Martinelli P, et al. Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology. 2014;82(15):1362–9.CrossRefPubMed
61.
• Zange L, Noack C, Hahn K, Stenzel W, Lipp A. Phosphorylated alpha-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Brain. 2015;138(Pt 8):2310–21. Description of α-syn deposits in skin sympathetic nerve fibers around sweat glands in PD but not in MSA patients. The study also reported decreased density of the fibers innervating autonomic skin structures in PD but not in MSA.CrossRefPubMed
62.
• Doppler K, Weis J, Karl K, Ebert S, Ebentheuer J, Trenkwalder C, et al. Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy. Mov Disord. 2015;30(12):1688–92. Description of distinct patterns of α-syn deposition in the skin of patients with MSA (mainly somatosensory fibers of the subepidermal plexus) and PD (prominent in autonomic fibers).CrossRefPubMed
63.
Haga R, Sugimoto K, Nishijima H, Miki Y, Suzuki C, Wakabayashi K, et al. Clinical utility of skin biopsy in differentiating between parkinson's disease and multiple system atrophy. Parkinsons Dis. 2015;2015:167038.PubMedPubMedCentral
64.
Provitera V, Nolano M, Caporaso G, Stancanelli A, Manganelli F, Iodice R, et al. Post-ganglionic sudomotor denervation in patients with multiple system atrophy. Neurology. 2014;82(24):2223–9.CrossRefPubMed
65.
Corbille AG, Letournel F, Kordower JH, Lee J, Shanes E, Neunlist M, et al. Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies. Acta Neuropathol Commun. 2016;4:35.CrossRefPubMedPubMedCentral
66.
Pouclet H, Lebouvier T, Coron E, Rouaud T, Flamant M, Toulgoat F, et al. Analysis of colonic alpha-synuclein pathology in multiple system atrophy. Parkinsonism Relat Disord. 2012;18(7):893–5.CrossRefPubMed
67.
Chung SJ, Kim J, Lee HJ, Ryu HS, Kim K, Lee JH, et al. Alpha-synuclein in gastric and colonic mucosa in Parkinson's disease: limited role as a biomarker. Mov Disord. 2016;31(2):241–9.CrossRefPubMed
68.
Valera E, Monzio Compagnoni G, Masliah E. Review: novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy. Neuropathol Appl Neurobiol. 2016;42(1):95–106.CrossRefPubMedPubMedCentral
69.
Dehay B, Decressac M, Bourdenx M, Guadagnino I, Fernagut PO, Tamburrino A, et al. Targeting alpha-synuclein: therapeutic options. Mov Disord. 2016;31(6):882–8.CrossRefPubMed
70.
Sturm E, Fellner L, Krismer F, Poewe W, Wenning GK, Stefanova N. Neuroprotection by epigenetic modulation in a transgenic model of multiple system atrophy. Neurotherapeutics. 2016;13(4):871–879.
71.
• Mandler M, Valera E, Rockenstein E, Mante M, Weninger H, Patrick C, et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener. 2015;10:10. Proof of concept showing beneficial effects of active vaccination with AFF1 (corresponds to Affitope PD01A in human trials) in transgenic MSA mice on accumulation of α-syn, demyelination, and neurodegeneration.CrossRefPubMedPubMedCentral
72.
• Bassil F, Fernagut PO, Bezard E, Pruvost A, Leste-Lasserre T, Hoang QQ, et al. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci USA. 2016;113(34):9593–8. Proof of concept of the ability of the caspase-1 inhibitor prodrug VX-765 to mitigate α-syn pathology and to mediate neuroprotection in transgenic MSA mice. VX-765 prevented motor deficits in PLP-SYN, reduced the levels of truncated α-syn and showed neuroprotective effects by preserving dopamine neurons in the substantia nigra.CrossRefPubMedPubMedCentral
73.
Spencer B, Valera E, Rockenstein E, Trejo-Morales M, Adame A, Masliah E. A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy. Mol Neurodegener. 2015;10:48.CrossRefPubMedPubMedCentral
74.
Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol. 2008;210(2):421–7.CrossRefPubMed
75.
Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spencer B, et al. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of alpha-synucleinopathy. Exp Neurol. 2012;234(2):405–16.CrossRefPubMedPubMedCentral
76.
Ubhi K, Rockenstein E, Mante M, Patrick C, Adame A, Thukral M, et al. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport. 2008;19(13):1271–6.CrossRefPubMedPubMedCentral
77.
Kaindlstorfer C, Sommer P, Georgievska B, Mather RJ, Kugler AR, Poewe W, et al. Failure of neuroprotection despite microglial suppression by delayed-start myeloperoxidase inhibition in a model of advanced multiple system atrophy: clinical implications. Neurotox Res. 2015;28(3):185–94.CrossRefPubMedPubMedCentral
78.
Stefanova N, Georgievska B, Eriksson H, Poewe W, Wenning GK. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox Res. 2012;21(4):393–404.CrossRefPubMed
79.
Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65(1):101–7.CrossRefPubMed
80.
Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, Phase 3 trial. Neurology. 2014;83(4):328–35.CrossRefPubMedPubMedCentral
81.
Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(3):268–75.CrossRefPubMedPubMedCentral
82.
Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, et al. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomized, placebo-controlled trial. Lancet Neurol. 2015;14(2):145–52.CrossRefPubMed
83.
Rascol O. French MSA-Fluoxetine Study Group. Preliminary results of the French MSA-fluoxetine study. Eur J Neurol. 2012;19 Suppl 1:262.
84.
Tada M, Kakita A, Toyoshima Y, Onodera O, Ozawa T, Morita T, et al. Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death. Brain. 2009;132(Pt 7):1810–9.CrossRefPubMed
85.
Lee PH, Lee JE, Kim HS, Song SK, Lee HS, Nam HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol. 2012;72(1):32–40.CrossRefPubMed
86.
Sacca F, Marsili A, Quarantelli M, Brescia Morra V, Brunetti A, Carbone R, et al. A randomized clinical trial of lithium in multiple system atrophy. J Neurol. 2013;260(2):458–61.CrossRefPubMed
Metadaten
Titel
Multiple System Atrophy - State of the Art
verfasst von
Brice Laurens
Sylvain Vergnet
Miguel Cuina Lopez
Alexandra Foubert-Samier
François Tison
Pierre-Olivier Fernagut
Wassilios G. Meissner
Publikationsdatum
01.05.2017
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 5/2017
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-017-0751-0

Weitere Artikel der Ausgabe 5/2017

Current Neurology and Neuroscience Reports 5/2017 Zur Ausgabe

Pediatric Neurology (WE Kaufmann, Section Editor)

Reflections on Ethics and Humanity in Pediatric Neurology: the Value of Recognizing Ethical Issues in Common Clinical Practice

Pediatric Neurology (WE Kaufmann, Section Editor)

A Novel Way to Measure and Predict Development: A Heuristic Approach to Facilitate the Early Detection of Neurodevelopmental Disorders

Neuro-Ophthalmology (A Kawasaki, Section Editor)

The Spectrum of Vestibular and Ocular Motor Abnormalities in Thiamine Deficiency

Epilepsy (CW Bazil, Section Editor)

Genetic Testing in Pediatric Epilepsy

Epilepsy (CW Bazil, Section Editor)

Cognitive and Behavioral Interventions in Epilepsy

Sleep (M Thorpy and M Billiard, Section Editors)

Sleep Disordered Breathing in Duchenne Muscular Dystrophy

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise